News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
FUSEN PHARM (01652.HK) Lornoxicam for Injection Approved for Marketing
FUSEN PHARM (01652.HK) announced that "Lornoxicam for Injection", developed by its wholly-owned subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, has received marketin...
Reset
Send
The window will close in 5 seconds
FUSEN PHARM (01652.HK) Lornoxicam for Injection Approved for Marketing
Close
Recommend
2
Positive
2
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

FUSEN PHARM (01652.HK)  0.000 (0.000%)   announced that "Lornoxicam for Injection", developed by its wholly-owned subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, has received marketing approval from the National Medical Products Administration of China. The product is approved for the short-term treatment of acute moderate pain after surgery. (ha/u)(HK stocks quote is delayed for at least 15 mins.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.